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Abstract : Colorectal neuroendocrine carcinoma（NEC）is extremely rare and 
has a dismal prognosis.  However, no standardized treatment strategy has been 
established for this lesion.  For patients with NEC and distant metastasis, disease 
stabilization is difcult even after treatment with multidisciplinary strategies includ-
ing chemotherapy.  Here we describe a case of rectal NEC that presented as 
multiple liver metastases; a favorable prognosis was obtained after treatment with 
a multidisciplinary strategy that included surgery, irradiation, and chemotherapy.  A 
66-year-old male presented with diarrhea and constipation.  Colonoscopy and a 
computed tomography（CT）scan revealed a rectal mass involving all of the lumi-
nal circumference, after which a diagnosis of NEC was conrmed by pathological 
examination.  A CT scan also revealed several liver metastases in S5, S6, and S8.  
Abdominoperineal resection with total mesenteric excision and lymphadenectomy, 
including the lateral area, was performed.  After resection, we administered radia-
tion for local disease control in the lateral area.  We also administered chemother-
apy consisting of cisplatin and irinotecan for the liver metastases because only the 
endocrine cell component constituted this tumor.  After chemotherapy, a CT scan 
was performed to conrm that the liver metastasis in S5 and S6 had disappeared, 
and it was shown that the other lesion in S8 had shrunk substantially（it eventu-
ally disappeared）.  Then, 48 months after resection, all metastatic liver tumors were 
under good control, and no other recurrent lesion was recognized.  In conclusion, a 
multidisciplinary strategy including optimal chemotherapy seems to be important to 
achieve a favorable prognosis of NEC of the colorectum with distant metastasis..
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Introduction
　According to the WHO 2019 classication1）, gastrointestinal neuroendocrine neoplasms are clas-
sied as G1, G2, or G3 NET（neuroendocrine tumors）or NEC（neuroendocrine carcinomas）, 
based on mitotic count, Ki67 labeling index, and pathological differentiation.  This classication 
considers cell differentiation and proliferation, but does not consider the mechanism of tumor 
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development and tumor origin, and thus, some confusion remains with regard to the histological 
classification.  NET and NEC are grouped as different categories because the mechanism of 
development of both tumors is different.  The origin of NEC seems to be adenocarcinoma, while 
NET arises from endocrine cell; in addition, NEC contains both neuroendocrine and adenocar-
cinoma components2）.  Regarding NEC of the colon and rectum, these two components have a 
distinct propensity to in uence the ef cacy of chemotherapy, and thus, the chemotherapy regimen 
selected for this lesion should be considered in association with the amount of these two com-
ponents3）.  Therefore, chemotherapy depends on which component is dominant in its contribution 
to the tumor, which seems to be necessary for good outcomes of colorectal NEC.  Here, we 
present a case of rectal NEC with multiple liver metastases that achieved a favorable prognosis 
after management with a multidisciplinary strategy, including chemotherapy, after consideration of 
the ratio of both the adenocarcinoma and neuroendocrine components.
Case report
　A-66-year-old male presented with diarrhea and constipation.  Colonoscopic examination 
revealed a rectal mass located 2 cm from the anal verge that involved the entire luminal circum-
ference; the biopsy con rmed a diagnosis of NEC（Fig. 1A）.  A computed tomography（CT）
scan was completed and revealed a large irregular mass surrounding the lower rectum, substan-
tial lymph node swelling（Fig. 1B）, and several liver lesions in S8（Fig. 2A）, S5（Fig. 2D）, and 
S6（Fig. 2G）, which were considered metastases.  However, no other metastases were observed. 
Abdominoperineal resection with total mesenteric excision and lymphadenectomy around the 
inferior mesenteric artery and lateral area was performed.  Gross  ndings of the lesion included 
the identi cation of two submucosal tumor-like masses with ulcers and several prominences.  On 
microscopic examination, small- to medium-sized cells with relatively scant cytoplasm that had 
Fig. 1.  Colonoscopy
A： Endoscopic view revealed a rectal mass located 2 cm from the anal 
verge that involved the entire luminal circumference.
B： Contrast-enhanced computed tomography scan revealed a large 
irregular mass surrounding the lower rectum with substantial lymph 
node swelling（arrows）.
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proliferated in nests or cords were seen.  The cells contained oval nuclei with granular chromatin 
and inconspicuous nucleoli.  Mitotic  gures were frequent.  No adenocarcinoma component was 
observed（Fig. 3A）.  Immunohistochemically, MIB-1 revealed positive nuclear staining in more 
than 60％ of all nuclei（Fig. 3B）, and most cells were positive for NCAM（CD56）（Fig. 3C）; 
Fig. 2.   Image of an abdominal contrast-enhanced computed tomography scan. 
Computed tomography scan revealed liver metastases before surgery（A, 
D, G）, after chemotherapy（B, E, H）, and at 48 months after surgery
（C, F, I）in S8（A, B, C）, S5（D, E, F）, and S6（G, H, I）（arrows）. 
All tumors had diminished（B）or disappeared after treatment（E, H）, 
and the patient did not experience recurrence（C, F, I）.
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moreover, approximately one-third of the cells were weakly positive for synaptophysin（Fig. 3D）, 
but chromogranin A was not expressed.  This tumor was con rmed as a small-cell-type NEC
（SCNEC）.  The tumor involved the full thickness of the rectal wall and 16 regional lymph 
nodes（of 29 examined nodes）; No 251, 253, and 283rt were metastatic nodes.
　The clinical and histopathological findings confirmed the diagnosis of neuroendocrine cell 
carcinoma of the rectum with lymph node and liver metastases.  After surgery, radiation therapy
（57 Gy）was administered for local control of the lateral lymph node area.  And chemotherapy 
with cisplatin（60 mg/m3 /cycle）and irinotecan（60 mg/m3 × 3 times/cycle）were initiated for liver 
metastases because this tumor was composed of only endocrine cell and did not contain adeno-
carcinoma cell.  After 6 chemotherapy cycles, a CT scan was performed to evaluate whether the 
liver metastases in S5（Fig. 2E）and S6（Fig. 2H）had disappeared and whether the other lesion 
in S8 had shrunk substantially（Fig. 2B）.  Then, 48 months after resection, the liver metastases 
had completely disappeared, and the tumor continued to regress（Fig. 2C, F, I）; no other recur-
rent lesion was observed（Fig. 4）.  
Fig. 3.  Histological and immunohistochemical examination of the tumor（Magnification 200×）
A： （H&E）By hematoxylin-eosin staining, small- to medium-sized cells with relatively scant 
cytoplasm that had proliferated in nests or cords were observed. The cells possessed 
oval nuclei with granular chromatin and inconspicuous nucleoli, and no adenocarcinoma 
component was recognized.
B： （MIB-1）MIB-1 immunohistochemistry revealed positive nuclear staining in up to 60％ 
of all nuclei.
C： （NCAM）Most cells were positive for NCAM（CD56）.
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Discussion
　Colorectal NEC is rare（accounts for less than 1％ of all colorectal adenocarcinomas）and is 
associated with an extremely poor prognosis because most patients have metastatic disease at 
the time of diagnosis 3）.  Treatment strategies of colorectal NEC are based on modalities extrapo-
lated from retrospective reports and are not based on prospective studies.  Actually, even today, 
patients with colorectal NEC in Japan are usually treated with several strategies, such as surgical 
resection and radiation, according to Japanese colorectal guideline4）.  However, in metastatic 
patients, the efcacy of surgical resection and radiation for this lesion is uncertain.  Although 
surgical resection for colorectal NEC with oncological excision of metastatic lymph nodes is the 
primary treatment for local disease control, it is not associated with superior outcomes except in 
patients with localized lesions and early disease5，6）.  Radiation also does not lead to a conclusive 
benet7，8）.  On the contrary, chemotherapy has been suggested to offer some benets and good 
control when systemic treatment is initiated earlier.  Published reports have conrmed two types 
of chemotherapy regimens: those that are platinum-based（cisplatin or carboplatin＋ etoposide 
or irinotecan ± paclitaxel）3，9，10） and those that are 5-FU-based（oxaliplatin or irinotecan＋ folinic 
acid＋ 5FU）3）.  The efcacy of platinum-based chemotherapy for NEC is based on lung car-
cinoma guidelines because the endocrine cell component of this neoplasm is similar to that of 
small-cell lung carcinoma10）.  Therefore, the regimen of cisplatin＋ irinotecan regimen planed 4-6 
cycles, is recommended in Japan11，12）.  
　Furthermore, NEC contains both endocrine and adenocarcinoma cell components; these inu-
ence the growth and biological behaviors of NEC, which depend on the ratio of these two 
components2）.  According to the Japanese classication13）, gastrointestinal NEC was classied as 
Fig. 4.  Schema of the treatment schedule
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4 different types based on the amount of the neuroendocrine and adenocarcinoma cell compo-
nents.  This classication differs from the WHO 2019 classication, which does not mention the 
ratio of these two components.  Smith et al 3） reported that 5-FU-based regimens were effective 
against the adenocarcinoma component, while platinum-based regimens were effective against the 
endocrine cell component.  According to these reports, chemotherapy for NEC is inuenced by 
the response of these two components（endocrine cell and adenocarcinoma）, and the chemo-
therapy regimen, which depends on the NEC components, seems to constitute a key role of the 
treatment strategy.  Therefore, to obtain a better response, we believe that chemotherapy should 
be selected after consideration of the biological behavior of the endocrine and adenocarcinoma 
components.
　In our case, only the endocrine cell component constituted the primary tumor, and no adeno-
carcinoma component was observed.  Therefore, a chemotherapy regimen consisting of cisplatin 
and irinotecan was selected.  After 6 courses of chemotherapy, two metastatic liver tumors in 3 
locations disappeared, and the other tumor was largely reduced.  As a result, this case achieved 
a long-term survival of 46 months after surgery on the image diagnosis.  Such cases of colorectal 
NEC with liver metastases that achieve long-term survival are rare in published reports, which 
have presented patients who have survived for 18, 1, and 4 months3，14，15）.  Despite the liver 
metastasis in our case, after local control by surgery and radiation therapy, platinum-based che-
motherapy was very effective, and long-term survival was achieved in our case.  The reason that 
chemotherapy may have been so effective was that it was selected based on the components of 
the tumor.  
　In conclusion, colorectal NEC is a rare and difcult tumor to treat.  However, multidisciplinary 
treatment, especially optimal chemotherapy in association with the component of this tumor, 
appears to be important to obtain adequate control.
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